Palvella Therapeutics (PVLA) Enterprise Value (2016 - 2024)
Historic Enterprise Value for Palvella Therapeutics (PVLA) over the last 12 years, with Q3 2024 value amounting to -$14.2 million.
- Palvella Therapeutics' Enterprise Value rose 7495.06% to -$14.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$14.2 million, marking a year-over-year increase of 7495.06%. This contributed to the annual value of -$16.3 million for FY2023, which is 7241.8% up from last year.
- As of Q3 2024, Palvella Therapeutics' Enterprise Value stood at -$14.2 million, which was up 7495.06% from -$14.5 million recorded in Q2 2024.
- In the past 5 years, Palvella Therapeutics' Enterprise Value ranged from a high of -$6.2 million in Q1 2024 and a low of -$125.1 million during Q3 2021
- Moreover, its 5-year median value for Enterprise Value was -$70.4 million (2020), whereas its average is -$68.8 million.
- Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 6719.29% in 2021, then surged by 8904.57% in 2024.
- Palvella Therapeutics' Enterprise Value (Quarter) stood at -$70.4 million in 2020, then plummeted by 67.19% to -$117.8 million in 2021, then surged by 49.76% to -$59.2 million in 2022, then soared by 72.42% to -$16.3 million in 2023, then rose by 12.95% to -$14.2 million in 2024.
- Its Enterprise Value stands at -$14.2 million for Q3 2024, versus -$14.5 million for Q2 2024 and -$6.2 million for Q1 2024.